• Galderma is calling on the rosacea community and their friends and family to submit artistic creations to Rosacea Space this Rosacea Awareness Month, illustrating what rosacea means to them
• Content from prominent artists and influencers will feature on the dedicated site www.rosaceaspace.com, connecting those impacted by rosacea worldwi

• Results from Phase 2 study published in the New England Journal of Medicine.

• Nemolizumab met the primary endpoint of a greater improvement in Peak Pruritus Numerical rating scale (PP-NRS) from baseline to Week 4 compared to placebo.

• Nemolizumab was recently granted FDA Breakthrough Therapy Designation for the treatment of patients suffering fro

First and Only Hyaluronic Acid Dermal Filler for Cheeks with Cannula¹ Now Offers Aesthetic Professionals New Delivery Method of Injectable Treatment 

Lausanne, Switzerland – November 17, 2020 – Galderma today announced top-line results from a Phase 2 study on the impact of dose escalation on the duration of effect and the efficacy and safety of a single dose of Dysport^® (abobotulinumtoxinA) for Injection (50U, 75U, 100U or 125U) versus placebo for the treatment of moderate to severe frown lines between th